MedTrace Logo

Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction

NCT03523624 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-05-25

No results posted yet for this study

Summary

In medical practice, a combination of clinical exam, electrocardiograms, circulating biomarkers, and imaging is used to gain insights on the prognosis after myocardial infarction. Novel molecular non-invasive tools are needed that help clinicians overcome the adverse events of post-myocardial infarction remodelling and thereby achieve improved therapy for its prevention.

Coagulation factor XIII (FXIII) decay has been linked to major adverse cardiac events (MACE) in patients with acute coronary syndromes. Given the correlation between both intramyocardial haemorrhage and microvascular damage with acute phase complications in ST-elevation myocardial infarction, we hypothesise that excessive FXIII decay within the first week may predict acute phase outcomes in these patients. If this holds true, FXIII determination could be used as diagnostic and prognostic tool.

Conditions

  • Factor XIII Deficiency
  • ST-Elevation Myocardial Infarction
  • Myocardial Haemorrhage
  • Coronary Microvascular Disease

Sponsors & Collaborators

  • University of Padova

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2019-03-01
Completion
2022-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523624 on ClinicalTrials.gov